US 11,834,493 B2
Antibody cocktail against SARS-CoV-2 spike protein
Matthew K. Robinson, Blue Bell, PA (US); Pavel Nikitin, Exton, PA (US); Michael John Morin, Salisbury, MA (US); Jillian Dimuzio, Exton, PA (US); Ray Howanski, Exton, PA (US); and John P. Dowling, Willow Grove, PA (US)
Assigned to IMMUNOME, INC., Exton, PA (US)
Filed by Immunome, Inc., Exton, PA (US)
Filed on Jan. 4, 2022, as Appl. No. 17/568,576.
Claims priority of provisional application 63/284,963, filed on Dec. 1, 2021.
Claims priority of provisional application 63/270,665, filed on Oct. 22, 2021.
Claims priority of provisional application 63/236,479, filed on Aug. 24, 2021.
Claims priority of provisional application 63/220,881, filed on Jul. 12, 2021.
Claims priority of provisional application 63/178,848, filed on Apr. 23, 2021.
Claims priority of provisional application 63/150,070, filed on Feb. 16, 2021.
Claims priority of provisional application 63/134,159, filed on Jan. 5, 2021.
Prior Publication US 2022/0235118 A1, Jul. 28, 2022
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); A61K 2039/507 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 35 Claims
 
1. An antibody or antigen binding fragment that binds a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein, wherein the antibody or antigen binding fragment thereof comprises
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 1, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 2;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 3, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 4;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 5, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 6;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 7, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 8;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 9, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 10;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 11, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 12;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 13, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 14;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 15, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 16;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 17, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 18;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 19, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 20;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 21, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 22;
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 23, and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 24; or
a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 25 and a LCVR comprising the amino acid sequence is set forth in SEQ ID NO: 26.